Catherine Schulte

Q: What is Catherine Schulte's success rate?

Catherine Schulte currently has a success rate of 100.

Q: What is the average return of Catherine Schulte's calls?

Their stock ratings have generated an average return of 38.08490200111882.

Baird | Healthcare

Catherine Schulte is an analyst from Baird specializing in the Healthcare sector. Ranked #308 out of 4771 analysts, they have issued 16 stock ratings with a success rate of 100.00% and an average return of 38.08%.

With 16 ratings to date, Catherine Schulte is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 100.00% and an average return of 38.08%, highlighting promising potential as their track record develops further.

#308

Out of 4771

Total Ratings

+100.00%

Success Rate

+38.08%

Average Return

Recent Ratings Analysis

TECH

Hold

Jun 26, 2026

Target

$73.00

Current

$72.08

Performance

1.52%

Catherine Schulte rated TECH as Neutral on Jun 26, 2026, setting a price target of 73. The Hold stance appears justified, as shares hovered around 72.08 with a 1.52% move.

A

Buy

May 26, 2026

Target

$156.00

Current

$143.12

Performance

24.37%

On May 26, 2026, A was given a Outperform rating by Catherine Schulte, with a target price of 156. The stock rallied 24.37% after the rating, narrowing the gap to the target of 156 and validating the bullish stance.

MTD

Hold

May 11, 2026

Target

$1194.00

Current

$1280.58

Performance

18.73%

MTD received a Neutral rating from Catherine Schulte on May 11, 2026, aiming for 1194. Investors saw gains of 18.73% that the cautious stance didn’t fully capture.

QGEN

Buy

Apr 29, 2026

Target

$43.00

Current

$42.13

Performance

25.35%

On Apr 29, 2026, Catherine Schulte published a Outperform outlook on QGEN, with a target of 43. Shares gained 25.35%, underscoring the accuracy of the bullish outlook toward 43.

TMO

Buy

Apr 24, 2026

Target

$639.00

Current

$603.18

Performance

—

Catherine Schulte on Apr 24, 2026 assigned TMO a Outperform rating, with a price target of 639. The recommendation remains pending validation as shares consolidate around 603.18.

DHR

Buy

Apr 22, 2026

Target

$245.00

Current

$200.58

Performance

8.99%

On Apr 22, 2026, Catherine Schulte reaffirmed DHR with a Outperform rating, targeting 245. The recommendation was supported by strong follow-through as the stock rose from 200.58 to 200.58.

CAI

Buy

Feb 27, 2026

Target

$28.00

Current

$24.04

Performance

19.36%

CAI was rated Outperform by Catherine Schulte on Feb 27, 2026, with a price objective of 28. A bullish response from the market helped close the gap of 3.96 to the target.

GRAL

Buy

Feb 20, 2026

Target

$113.00

Current

$77.56

Performance

54.47%

On Feb 20, 2026, Catherine Schulte initiated coverage on GRAL with a Outperform rating and target of 113. The stock’s climb of 54.47% since the call highlights the foresight in the rating.

TEM

Buy

Feb 17, 2026

Target

$59.00

Current

$58.74

Performance

11.76%

Catherine Schulte issued a Outperform recommendation for TEM on Feb 17, 2026, price target set at 59. Investors following the Buy call captured upside momentum, with shares now at 58.74.

GH

Buy

Feb 17, 2026

Target

$120.00

Current

$159.03

Performance

48.47%

On Feb 17, 2026, GH was evaluated by Catherine Schulte, who gave a Outperform rating and target of 120. This case illustrates how a timely bullish rating can translate into tangible gains of 48.47%.

EXAS

Buy

Nov 04, 2025

Target

$88.00

Current

$104.91

Performance

50.75%

Catherine Schulte rated EXAS as Outperform on Nov 04, 2025, setting a price target of 88. The call has proven timely, with shares rising 50.75% toward the price target of 88.

AVTR

Buy

Oct 24, 2025

Target

$17.00

Current

$14.88

Performance

-3.38%

On Oct 24, 2025, AVTR was given a Outperform rating by Catherine Schulte, with a target price of 17. The stock traded sideways with a -3.38% move, keeping the bullish thesis unresolved.

MRVI

Hold

Feb 26, 2025

Target

$3.00

Current

$6.73

Performance

107.08%

MRVI received a Neutral rating from Catherine Schulte on Feb 26, 2025, aiming for 3. Investors saw gains of 107.08% that the cautious stance didn’t fully capture.

Frequency Asked Questions

Who is Catherine Schulte?

Catherine Schulte is an analyst from Baird specializing in the Healthcare sector.

What is Catherine Schulte's success rate?

Catherine Schulte currently has a success rate of +100.00%.

How many ratings has Catherine Schulte issued?

Catherine Schulte has issued 16 stock ratings so far.

What is the average return of Catherine Schulte's calls?

Their stock ratings have generated an average return of +38.08%.

What is Catherine Schulte's ranking?

Catherine Schulte is ranked #308 out of 4771 analysts.

What types of ratings does Catherine Schulte give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Catherine Schulte?

You can follow Catherine Schulte by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Catherine Schulte?

Their latest rating was a Hold on TECH issued on 2026-06-26.